You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
廣生堂(300436.SZ):抗新冠口服藥I期臨牀試驗達到試驗預期目的
格隆匯 12-11 17:00

格隆匯12月11日丨廣生堂(300436.SZ)公佈,公司創新藥控股子公司福建廣生中霖生物科技有限公司的口服小分子廣譜抗新型冠狀病毒3CL蛋白酶抑制劑一類創新藥物GST-HG171片I期臨牀試驗已完成全部受試者入組和臨牀觀察並於近日取得臨牀研究總結報吿。研究結果顯示GST-HG171具有良好的安全性、耐受性和藥代動力學特徵,達到試驗預期目的,為即將開展的Ⅱ/Ⅲ期臨牀研究提供了重要依據,是公司新冠創新藥研發的重大進展。公司在國家藥審中心專家指導下,已高效完成GST-HG171的Ⅱ/Ⅲ期關鍵性註冊臨牀研究設計,正在申報組長單位倫理審批,努力為防疫踐行企業責任擔當。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account